Optimizing on smoke free legislation making the most of the opportunity.
Stop smoking service provision faces significant challenges in optimizing the opportunities raised through the smoke free legislation, which prohibits smoking in a public place. There are a number of innovations in service provision allowing a more tailored and flexible approach to stopping smoking, where the patient requirements are central. Innovations such as cut down then stop (CDTS), combination nicotine replacement therapy (NRT) use, and new drug therapy Champix all provide increased options for the smoker.
Croghan
Emma
E
Independent Public Health Nurse Consultant. emma@elcconsultancy.org
D001552:Benzazepines / Q000627:therapeutic use; D016642:Bupropion / Q000627:therapeutic use; D003663:Decision Trees; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006301:Health Services Needs and Demand; D006801:Humans; D009538:Nicotine / Q000627:therapeutic use; D018722:Nicotinic Agonists / Q000627:therapeutic use; D024802:Nurse's Role; D010347:Patient Care Planning; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D011633:Public Facilities / Q000331:legislation & jurisprudence*; D011810:Quinoxalines / Q000627:therapeutic use; D012907:Smoking / Q000453:epidemiology / Q000331:legislation & jurisprudence* / Q000523:psychology; D016540:Smoking Cessation / Q000331:legislation & jurisprudence* / Q000379:methods* / Q000523:psychology; D000074606:Smoking Prevention; D012944:Social Support; D006113:United Kingdom / Q000453:epidemiology; D000068580:Varenicline
D001552:Benzazepines; D018765:Dopamine Uptake Inhibitors; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D009538:Nicotine; D000068580:Varenicline